F Lordick

Summary

Affiliation: University of Heidelberg
Country: Germany

Publications

  1. ncbi PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
    Florian Lordick
    Department of Surgery, Clinic rechts der Isar, Technical University of Munich, Munich, Germany
    Lancet Oncol 8:797-805. 2007
  2. ncbi The evolving role of catumaxomab in gastric cancer
    Florian Lordick
    University of Heidelberg, National Center for Tumour Diseases, Department of Medical Oncology, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany
    Expert Opin Biol Ther 8:1407-15. 2008
  3. pmc Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial
    S Lorenzen
    Third Department of Internal Medicine Haematology Medical Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    Br J Cancer 99:1020-6. 2008
  4. doi [Tumor markers and biomarkers in squamous cell cancer of the head and neck]
    F Lordick
    Nationales Centrum fur Tumorerkrankungen, Medizinische Onkologie, Universitatsklinikum Heidelberg, Im Neuenheimer Feld 350, 69120, Heidelberg, Deutschland
    HNO 56:881-5. 2008
  5. ncbi [R1 resection in the surgery of upper gastrointestinal tumors: relevance and therapeutic consequences]
    F Lordick
    Nationales Centrum für Tumorerkrankungen NCT, Universitatsklinikum, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany
    Chirurg 78:792-801. 2007
  6. doi [Multidisciplinary treatment for adult soft tissue sarcoma]
    F Lordick
    Nationales Centrum für Tumorerkrankungen Medizinische Onkologie, Universitatsklinikum Heidelberg, Im Neuenheimer Feld 350, Heidelberg, Germany
    Chirurg 80:209-15. 2009
  7. doi [Treatment of gastric cancer]
    Florian Lordick
    Nationales Zentrum für Tumorerkrankungen, Universitatsklinikum Heidelberg, Heidelberg, Deutschland
    Onkologie 31:32-9. 2008
  8. ncbi European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer
    Florian Lordick
    National Centre for Tumour Diseases, Department of Medical Oncology, University of Heidelberg, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany
    Eur J Cancer 44:1807-19. 2008
  9. doi Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie
    S Lorenzen
    Third Department of Internal Medicine Hematology Medical Oncology, Technical University of Munich, Munich
    Ann Oncol 20:1667-73. 2009
  10. doi Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy
    S Lorenzen
    3rd Department of Internal Medicine, Hematology Medical Oncology, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Ann Oncol 24:2068-73. 2013

Collaborators

Detail Information

Publications71

  1. ncbi PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
    Florian Lordick
    Department of Surgery, Clinic rechts der Isar, Technical University of Munich, Munich, Germany
    Lancet Oncol 8:797-805. 2007
    ..We aimed to assess the feasibility of a PET-response-guided treatment algorithm and its potential effect on prognosis...
  2. ncbi The evolving role of catumaxomab in gastric cancer
    Florian Lordick
    University of Heidelberg, National Center for Tumour Diseases, Department of Medical Oncology, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany
    Expert Opin Biol Ther 8:1407-15. 2008
    ..Intraperitoneal administration of catumaxomab in patients with malignant ascites due to epithelial cancer significantly increased puncture-free survival...
  3. pmc Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial
    S Lorenzen
    Third Department of Internal Medicine Haematology Medical Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    Br J Cancer 99:1020-6. 2008
    ..Neoadjuvant weekly oxaliplatin 45 mg m(-2) plus CI-5FU 225 mg m(-2) with concurrent radiotherapy provides promising histological response rates and R0 resection rates in locally advanced OSCC...
  4. doi [Tumor markers and biomarkers in squamous cell cancer of the head and neck]
    F Lordick
    Nationales Centrum fur Tumorerkrankungen, Medizinische Onkologie, Universitatsklinikum Heidelberg, Im Neuenheimer Feld 350, 69120, Heidelberg, Deutschland
    HNO 56:881-5. 2008
    ....
  5. ncbi [R1 resection in the surgery of upper gastrointestinal tumors: relevance and therapeutic consequences]
    F Lordick
    Nationales Centrum für Tumorerkrankungen NCT, Universitatsklinikum, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany
    Chirurg 78:792-801. 2007
    ..Preoperative strategies for reducing the rate of R1 resections are presented, and the surgical options in case of R1 resection are discussed...
  6. doi [Multidisciplinary treatment for adult soft tissue sarcoma]
    F Lordick
    Nationales Centrum für Tumorerkrankungen Medizinische Onkologie, Universitatsklinikum Heidelberg, Im Neuenheimer Feld 350, Heidelberg, Germany
    Chirurg 80:209-15. 2009
    ....
  7. doi [Treatment of gastric cancer]
    Florian Lordick
    Nationales Zentrum für Tumorerkrankungen, Universitatsklinikum Heidelberg, Heidelberg, Deutschland
    Onkologie 31:32-9. 2008
    ..If docetaxel is given in addition to platinum/5-FU, this doubles 2-year survival (with significant toxicity). Targeted drugs such as cetuximab, panitumumab, and bevacizumab are currently undergoing clinical trials...
  8. ncbi European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer
    Florian Lordick
    National Centre for Tumour Diseases, Department of Medical Oncology, University of Heidelberg, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany
    Eur J Cancer 44:1807-19. 2008
    ..This paper reviews the lectures and discussions held during this workshop and summarises the action points for the further investigation of metabolic imaging to guide treatment in gastrointestinal tumours...
  9. doi Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie
    S Lorenzen
    Third Department of Internal Medicine Hematology Medical Oncology, Technical University of Munich, Munich
    Ann Oncol 20:1667-73. 2009
    ..This study assessed the activity of the mAb cetuximab in combination with cisplatin and 5-fluorouracil (5-FU) in advanced esophageal squamous cell carcinoma...
  10. doi Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy
    S Lorenzen
    3rd Department of Internal Medicine, Hematology Medical Oncology, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Ann Oncol 24:2068-73. 2013
    ....
  11. ncbi Visualisation of metastatic oesophageal and gastric cancer and prediction of clinical response to palliative chemotherapy using 18FDG PET
    S Lorenzen
    3rd Department of Internal Medicine Haematology Medical Oncology, Klinikum rechts der Isar, Technical University, Ismaninger Strasse 22, Munich, Germany
    Nuklearmedizin 46:263-70. 2007
    ..This study assessed the value of (18)F-deoxyglucose positron emission tomography (FDG-PET) for visualisation and early metabolic response assessment in metastatic gastro-oesophageal cancer...
  12. ncbi Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial
    S Lorenzen
    Technical University Munich, 3rd Department of Internal Medicine Hematology Medical Oncology, Munich, Germany
    Ann Oncol 18:1673-9. 2007
    ..To reduce toxicity while maintaining the efficacy of DCF, we investigated split doses of docetaxel (T), cisplatin (P), leucovorin (L) and fluorouracil (F)...
  13. pmc Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    F Lordick
    Klinikum rechts der Isar, 3rd Medical Department, Technische Universitat Munchen, Ismaninger Strasse 22, 81675 Munich, Germany
    Br J Cancer 102:500-5. 2010
    ..Cetuximab enhances the efficacy of chemotherapy in several cancer types. This trial assessed the activity of cetuximab and chemotherapy in advanced gastric cancer...
  14. pmc Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial
    S Lorenzen
    3rd Department of Internal Medicine Haematology Medical Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, Munich D 81675, Germany
    Br J Cancer 92:2129-33. 2005
    ..Therefore, the combination merits further investigation in this setting...
  15. doi A reliable risk score for stage IV esophagogastric cancer
    S Blank
    Department of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
    Eur J Surg Oncol 39:823-30. 2013
    ..The role of surgery for patients with metastatic esophagogastric adenocarcinoma (EGC) is not defined. The purpose of this study was to define selection criteria for patients who may benefit from resection following systemic chemotherapy...
  16. ncbi Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma
    Kathrin Abbrederis
    Third Department of Medicine Hematology Oncology, Institute for Medical Statistics and Epidemiology, and Munich Center for Clinical Studies, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
    Ann Thorac Surg 82:293-7. 2006
    ..In a previous study we showed that many patients with esophagogastric adenocarcinoma experience anemia during neoadjuvant chemotherapy. We now investigated the role of erythropoietin in managing anemia during neoadjuvant chemotherapy...
  17. ncbi Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas
    T Schmidt
    Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
    Br J Cancer 110:1712-20. 2014
    ..This exploratory retrospective study analyses independent prognostic factors within a large patient cohort after preoperative chemotherapy including clinical and histopathological factors...
  18. doi [Indications for pre- and postoperative treatment with imatinib for gastrointestinal stromal tumors]
    U Heger
    Klinik fur Chirurgie, Universitatsklinikum, Im Neuenheimer Feld 350, Heidelberg, Germany
    Chirurg 79:630-7. 2008
    ..Therefore adjuvant treatment with imatinib is not yet approved nor is it a standard of care at this stage. The inclusion of patients with intermediate- and high-risk resected GIST into clinical studies is strongly recommended...
  19. ncbi [Response prediction--early response evaluation. Consequences for surgical oncology]
    J R Siewert
    Chirurgische Klinik, Klinikum rechts der Isar, Technische Universitat, Ismaninger Strasse 22, 81675, Munchen, Deutschland
    Chirurg 77:1095-103. 2006
    ..In the following, we delineate the current knowledge on response prediction and early response evaluation in selected tumor entities and draw possible conclusions for clinical practice and future clinical studies...
  20. pmc Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer
    F Lordick
    1Clinic Rechts der Isar, Technical University of Munich, Ismaninger Str 22, 81675 Munich, Germany
    Br J Cancer 93:190-4. 2005
    ..4 months (95% CI, 8.0-14.9 months) and the median time to progression is 6.5 months (95% CI, 3.9-9.2 months). The weekly FUFOX regimen is well tolerated and shows notable activity as first-line treatment in metastatic gastric cancer...
  21. doi Limited resection and free jejunal graft interposition for squamous cell carcinoma of the cervical oesophagus
    K Ott
    Department of Surgery, University of Heidelberg, Heidelberg, Germany
    Br J Surg 96:258-66. 2009
    ..Treatment options range from definitive radiotherapy to multimodal treatment. Outcome after limited resection and reconstruction with a free jejunal graft interposition was evaluated retrospectively...
  22. doi Weekly docetaxel monotherapy for advanced gastric or esophagogastric junction cancer. Results of a phase II study in elderly patients or patients with impaired performance status
    K Abbrederis
    3rd Department of Medicine Hematology Medical Oncology, Klinikum rechts der Isar, Technical University of Munich, Germany
    Crit Rev Oncol Hematol 66:84-90. 2008
    ..Three-weekly docetaxel is active in patients with advanced esophagogastric cancer but myelosuppression may make this schedule unsuitable for some patient groups such as elderly, pretreated, or poor performance status patients...
  23. ncbi Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome
    Joerg R Siewert
    Department of Surgery, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Ann Surg 246:624-8; discussion 628-31. 2007
    ..To study the impact of induction chemotherapy on surgical risk and outcome in locally advanced Barrett cancer...
  24. ncbi Neoadjuvant therapy for oesophagogastric cancer
    F Lordick
    Department of Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, D 81675 Munich, Germany
    Br J Surg 91:540-51. 2004
    ..The prognosis after surgery for oesophagogastric cancer remains poor...
  25. pmc Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer
    F Lordick
    3rd Department of Internal Medicine Haematology Medical Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str 22, D 81675 Munich, Germany
    Br J Cancer 89:630-3. 2003
    ..5 (range 16-51) weeks. Although the nonhaematological toxicity proved to be considerable, weekly irinotecan plus docetaxel is feasible and shows some activity in extensively pretreated patients with oesophageal cancer...
  26. ncbi Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction
    Katja Ott
    Department of Surgery, Technische Universitaet Muenchen, Ismaningerstr 22, D 81675, Munich, Germany
    J Clin Oncol 24:4692-8. 2006
    ..The aim of this study was to prospectively validate these findings by using an a priori definition of metabolic response...
  27. ncbi Delays in diagnosis and therapy of gastric cancer and esophageal adenocarcinoma
    R Witzig
    Department of Surgery, Klinikum rechts der Isar, Technical University of Munich, Germany
    Endoscopy 38:1122-6. 2006
    ....
  28. ncbi Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction
    Hinrich A Wieder
    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 46:2029-34. 2005
    ..We evaluated the temporal relationship between chemotherapy-induced changes in tumor glucose use and tumor size...
  29. doi Results of a multimodal therapy in patients with stage IV Barrett's adenocarcinoma
    Matthias Schauer
    Department of Surgery, Klinikum rechts der Isar, Technische Universitaet Muenchen, Ismaninger Strasse 22, 81675, Munich, Germany
    World J Surg 32:2655-60. 2008
    ..The benefit of a multimodal therapy concept in patients with stage IV disease remains unclear...
  30. ncbi Histopathological response after preoperative radiochemotherapy in rectal carcinoma is associated with improved overall survival
    R Rosenberg
    Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    J Surg Oncol 97:8-13. 2008
    ..Our aims were to determine outcome and impact of histopathological response after preoperative RCTX...
  31. doi [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint]
    K Ott
    Chirurgische Klinik, Universitat Heidelberg, Heidelberg
    Chirurg 80:1028-34. 2009
    ..Patients with locally advanced gastric cancer should always be referred to experienced high volume centers, where the findings are discussed in a multidisciplinary tumor board...
  32. ncbi Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients
    Katja Ott
    Department of Surgery, University Hospital of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany
    Int J Colorectal Dis 23:773-82. 2008
    ..Therefore, glutathione-S-transferase (GST) polymorphisms were assessed as predictive markers in cisplatinum-based neoadjuvant-treated gastric cancer...
  33. ncbi Surgical factors influence the outcome after Ivor-Lewis esophagectomy with intrathoracic anastomosis for adenocarcinoma of the esophagogastric junction: a consecutive series of 240 patients at an experienced center
    Katja Ott
    Department of Surgery, University of Heidelberg, Heidelberg, Germany
    Ann Surg Oncol 16:1017-25. 2009
    ..Thus, we evaluated the surgical risk and outcome after an abdominothoracic esophagectomy (Ivor-Lewis) with intrathoracic anastomosis as standard procedure...
  34. doi The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies
    Katja Ott
    Department of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, Heidelberg, Germany
    Gastric Cancer 11:1-9. 2008
    ....
  35. ncbi The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas
    Björn L D M Brücher
    Department of Surgery, Technical University of Munich, Munich, Germany
    Cancer 106:2119-27. 2006
    ..g., postoperative morbidity and mortality, recurrence, and survival) in patients with locally advanced esophageal squamous cell carcinoma (ESCC)...
  36. ncbi Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients
    Rudolf Napieralski
    Department of Pathology, Technische Universitat Munchen, Munich, Germany
    Clin Cancer Res 11:3025-31. 2005
    ..We evaluated the expression of seven therapy-related genes to predict the clinical outcome of advanced gastric cancer patients treated with a neoadjuvant chemotherapeutic protocol...
  37. ncbi [Importance of PET in surgery of esophageal cancer]
    K Ott
    Chirurgische Klinik, Universitat Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland
    Chirurg 85:505-12. 2014
    ....
  38. ncbi The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers
    A Ihbe-Heffinger
    Department of Pharmacy, Klinikum rechts der Isar, Technische Universitat Munchen, Germany
    Ann Oncol 15:526-36. 2004
    ..An additional aim of this study was to estimate costs imputable to CINV in the German healthcare environment...
  39. ncbi [Bevacizumab (Avastin) related surgical complications: comment to Abbrederis K et al. (2007)]
    F Lordick
    Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany
    Chirurg 79:356-60. 2008
  40. ncbi Proteomics in gastrointestinal cancer
    M P A Ebert
    Department of Medicine II, Klinikum rechts der Isar, Technische Universitat Munchen, Germany
    Ann Oncol 17:x253-8. 2006
  41. ncbi The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib
    C Miething
    Department of Internal Medicine III, Klinikum rechts der Isar, Technical University of Munich, Trogerstr, Munich, Germany
    Leukemia 20:650-7. 2006
    ..Thus, the analysed Bcr-Abl mutants confer imatinib resistance, but do not induce a growth advantage in the absence of imatinib...
  42. ncbi Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial
    Katja Ott
    Department of Surgery, Technische Universitä München, Munich, Germany
    J Clin Oncol 21:4604-10. 2003
    ..We prospectively evaluated the predictive value of therapy-induced reduction of tumor glucose use for subsequent response and patient survival in patients with gastric cancer treated by preoperative chemotherapy...
  43. ncbi Recent advances in multimodal treatment for gastric cancer: a review
    Florian Lordick
    Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str 22, D 81675 Munich, Germany
    Gastric Cancer 8:78-85. 2005
    ..Adjuvant chemoradiation has been shown to be beneficial in gastric cancer patients who have undergone suboptimal surgical resection. The benefits of adjuvant chemotherapy alone seem to be very small...
  44. ncbi The thymidylate synthase tandem repeat promoter polymorphism: A predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer
    Katja Ott
    Department of Surgery, Technical University, Munich, Germany
    Int J Cancer 119:2885-94. 2006
    ..93). Patients' survival after CTx was associated with the TS tandem repeat polymorphism. CTx did not improve survival of patients with the 3rpt/3rpt genotype. Thus, a different therapy might be more appropriate for these patients...
  45. ncbi Current treatment approach to locally advanced esophageal cancer: is resection mandatory?
    Florian Lordick
    Department of Surgery and Medical Oncology, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Str 22, D 81675 Munich, Germany
    Future Oncol 2:717-21. 2006
    ..Response to induction chemotherapy and radiation will determine future treatment algorithms, and promising tools for predicting response are currently being investigated...
  46. ncbi Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction
    Hinrich A Wieder
    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitaet Muenchen, Ismaningerstrasse 22, Munich, Germany
    Eur J Nucl Med Mol Imaging 34:1925-32. 2007
    ..To address this question we studied the time course of changes in tumor FDG-uptake in patients with locally advanced adenocarcinomas of the esophagogastric junction (AEG) treated with preoperative chemotherapy...
  47. doi Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study
    Katja Ott
    Department of Surgery, Technische Universitat Munchen, Munich, Germany
    Clin Cancer Res 14:2012-8. 2008
    ..The goal of the study was the definition of biologically different groups of patients prior to or early during induction therapy, with special emphasis on FDG non-avid tumors...
  48. ncbi Methylation of tumor-related genes in neoadjuvant-treated gastric cancer: relation to therapy response and clinicopathologic and molecular features
    Rudolf Napieralski
    Department of Pathology, Technische Universitat Munchen, Munich, Germany
    Clin Cancer Res 13:5095-102. 2007
    ..Furthermore, we analyzed the relationship of promoter hypermethylation with microsatellite instability and loss of heterozygosity (LOH) of the tumors...
  49. doi Paclitaxel in the neoadjuvant treatment for adeno carcinoma of the distal esophagus (AEG I). A comparison of two phase II trials with long-term follow-up
    Franz G Bader
    Department of Surgery, University of Schleswig Holstein, Campus Lubeck, Germany
    Onkologie 31:366-72. 2008
    ..We report a comparative analysis of 2 sequential, prospective phase II trials on the efficacy of platinum/leucovorin/5-fluorouracil (PLF) +/- paclitaxel (T-PLF) in the neoadjuvant treatment of adenocarcinoma of the esophagus (AEG I)...
  50. doi Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion
    K Potthoff
    Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany
    Ann Oncol 22:524-35. 2011
    ..Material and methods: An expert panel from Germany with expertise in medical oncology, dermatology or clinical pharmacology was convened to develop expert recommendations based on published peer-reviewed literature...
  51. doi Phenotyping of tumor biology in patients by multimodality multiparametric imaging: relationship of microcirculation, alphavbeta3 expression, and glucose metabolism
    Stephan Metz
    Department of Radiology, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 51:1691-8. 2010
    ..We analyzed the spatial relationship of α(v)β(3) expression, glucose metabolism, and perfusion by PET and DCE MRI, focusing on tumor heterogeneity...
  52. ncbi Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG
    Ambros J Beer
    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 49:22-9. 2008
    ..We evaluated whether assessment of alpha(v)beta(3) expression and of glucose metabolism with PET using (18)F-galacto-RGD and (18)F-FDG provides complementary information in cancer patients...
  53. ncbi Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis
    Ken Herrmann
    Department of Nuclear Medicine, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 48:1945-50. 2007
    ..In this pilot study, we evaluated 3'-deoxy-3'-(18)F-fluorothymidine (FLT) PET for the detection of gastric cancer and compared the diagnostic accuracy with that of (18)F-FDG PET...
  54. doi Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant
    Kathrin Abbrederis
    3 Medizinische Klinik Hamatologie Onkologie, Munich, Germany
    Onkologie 32:30-4. 2009
    ..It is also unknown whether aprepitant, a neurokinin-1 receptor antagonist, can be used as secondary antiemetic prophylaxis in case of CINV during cycle 1...
  55. doi The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT
    Robert Rosenberg
    Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universitat Munchen, Ismaningerstr 22, 81675, Munich, Germany
    Int J Colorectal Dis 24:191-200. 2009
    ....
  56. ncbi Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response
    Rupert Langer
    Institute of Pathology, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Clin Cancer Res 14:8279-87. 2008
    ....
  57. doi Remission of paraneoplastic dermatomyositis associated with hepatocellular carcinoma under prednisolone and azathiopin, and concommittant sorafenib
    Leonidas Apostolidis
    Department of Medical Oncology, National Center for Tumor Diseases, Universitat Heidelberg, Im Neuenheimer Feld 350, Heidelberg, Germany
    Onkologie 32:50-3. 2009
    ..Dermatomyositis is a known paraneoplastic syndrome that can complicate the course of a variety of different cancers, however, the association with HCC is extremely rare...
  58. doi Immunohistochemical detection of receptor tyrosine kinases c-kit, EGF-R, and PDGF-R in colorectal adenocarcinomas
    Jan Friederichs
    Department of Surgery, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Langenbecks Arch Surg 395:373-9. 2010
    ..This study aimed to clarify expression patterns of therapeutically addressable receptor tyrosine kinases in colorectal cancer...
  59. ncbi Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy
    Ambros J Beer
    Department of Radiology, Technische Universitaet Muenchen, Klinikum rechts der Isar, Ismaninger Str 22, 81675 Munich, Germany
    Radiology 239:472-80. 2006
    ..To prospectively evaluate multi-detector row computed tomography (CT) in the assessment of early response during neoadjuvant chemotherapy for adenocarcinoma of the esophagogastric junction (AEG)...
  60. ncbi PET imaging with [18F]3'-deoxy-3'-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer
    Hinrich A Wieder
    Department of Nuclear Medicine, Technische Universitat Munchen, Munchen, Germany
    Eur J Nucl Med Mol Imaging 34:878-83. 2007
    ..Positron emission tomography (PET) using 18F-labelled 3'-deoxy-3'-fluorothymidine (FLT) was assessed for therapy monitoring in patients with rectal cancer undergoing neoadjuvant chemoradiotherapy...
  61. ncbi Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment
    Hinrich A Wieder
    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitaet Muenchen, Ismaningerstrasse 22, D 81675 Munich, Germany
    J Clin Oncol 22:900-8. 2004
    ....
  62. ncbi Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer
    Verena Voelter
    Centre Hospitalier Universitaire Vaudois, Multidisciplinary Oncology Center, Lausanne, Switzerland
    Ann Thorac Surg 78:1037-41. 2004
    ..Patients who are treated with neoadjuvant chemotherapy with a curative intent are exposed to toxicity that may negatively affect their future outcome...
  63. ncbi Comparison of pretherapeutic and posttherapeutic expression levels of chemotherapy-associated genes in adenocarcinomas of the esophagus treated by 5-fluorouracil- and cisplatin-based neoadjuvant chemotherapy
    Rupert Langer
    Institute of Pathology, Klinikum rechts der Isar, Technische Universitat, Munchen, Germany
    Am J Clin Pathol 128:191-7. 2007
    ..Down-regulation of chemotherapy metabolism-associated genes occurs after neoadjuvant chemotherapy and may modulate tumor response to chemotherapy...
  64. ncbi Antibody-based targeted therapy for gastric cancer
    Florian Lordick
    Gastric Cancer 8:206-8. 2005
  65. ncbi Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group
    Eric Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg, 3000 Leuven, Belgium
    Eur J Cancer 44:182-94. 2008
    ..The addition of biological agents to the optimal chemotherapy regimen may achieve further improvements in efficacy...
  66. ncbi Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer
    Claus Rodel
    Department of Radiation Therapy, Friedrich Alexander University of Erlangen Nuremberg, Erlangen, Germany
    Int J Radiat Oncol Biol Phys 70:1081-6. 2008
    ..To evaluate the safety and activity of preoperative radiotherapy (RT) with concurrent cetuximab, capecitabine, and oxaliplatin in rectal cancer patients...
  67. ncbi Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany
    Florian Lordick
    Third Medical Department, Klinikum rechts der Isar, Technische Universitat Munchen, Ismaninger Str 22, 81675 Munchen, Germany
    Eur J Cancer 43:299-307. 2007
    ..We aimed to determine outcomes associated with use of aprepitant in outpatients undergoing highly emetogenic chemotherapy in Germany from a patient's and payer's perspective...
  68. ncbi Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer
    Claus Rodel
    Department of Radiotherapy, University of Erlangen Nurnberg, Erlangen, Germany
    J Clin Oncol 25:110-7. 2007
    ..To evaluate the activity and safety of preoperative radiotherapy (RT) and concurrent capecitabine and oxaliplatin (XELOX-RT) plus four cycles of adjuvant XELOX in patients with rectal cancer...
  69. ncbi Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer
    Howard Hochster
    Cancer Institute, New York University Medical Center, 160 East 34th Street, 9th Floor, New York, NY 10016, USA
    Clin Colorectal Cancer 5:257-62. 2005
    ..The distinct mechanisms of action and patterns of resistance displayed by pemetrexed and irinotecan make them attractive agents for combination therapy...
  70. ncbi [Interdisciplinary psychoeducational intervention by oncologists proved helpful for cancer patients]
    Harald Gündel
    Institut und Poliklinik für Psychosomatische Medizin, Psychotherapie und Medizinische Psychologie, TU Munchen, Klinikum rechts der Isar, Langerstr 3, 81675 Munchen, Germany
    Z Psychosom Med Psychother 49:246-61. 2003
    ..We prospectively evaluated the effects of a six-session psychoeducational intervention held by medical doctors or psychologists in a German acute cancer center setting...
  71. ncbi Rectal cancer: MR imaging before neoadjuvant chemotherapy and radiation therapy for prediction of tumor-free circumferential resection margins and long-term survival
    Hinrich A Wieder
    Department of Radiology, Technische Universitat Munchen, Klinikum rechts der Isar, Ismaningerstrasse 22, 81675 Munich, Germany
    Radiology 243:744-51. 2007
    ..To retrospectively evaluate the prognostic importance of involvement of the circumferential resection margin predicted by using magnetic resonance (MR) imaging before neoadjuvant treatment in patients with rectal cancer...